A urine-based methylation signature for risk stratification within low-risk prostate cancer

British Journal of Cancer

Volumn 112, Issue 5, 2015, Pages 802-808

  Jatkoe, T A ^a   Karnes, R J ^b   Freedland, S J ^c,d   Wang, Y ^a   Le, A ^a   Baden, J ^a  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; APC PROTEIN; APC PROTEIN, HUMAN; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; GENETIC RISK; GLEASON SCORE; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL; NEEDLE BIOPSY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; URINALYSIS; CANCER GRADING; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; STATISTICAL MODEL; URINE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; DNA METHYLATION; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM GRADING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84928696411     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.7     Document Type: Article

References (36)

1. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319.
2. American Cancer Society (2013) Cancer Facts &Figures 2013. American Cancer Society: Atlanta, GA, USA.
3. Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J, Trust C, Wang Y, Green G (2011) Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol 186: 2101-2106.
4. Barocas DA, Cowan JE, Smith Jr JA, Carroll PR. CaPSURE Investigators (2008) What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 180: 1330-1334.
5. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037-4043.
6. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28: 1117-1123.
7. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173: 1938-1942.
8. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey Jr DE, Wallace ME, Kantoff PW, Carroll PR (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112: 1650-1659.
9. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101: 374-383.
10. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, Wernert N, Müller SC, von Ruecker A (2008) CpG island hyper-methylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161-167.
11. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R (2005) Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 11: 6582-6588.
12. Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from prostate to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61: 1019-1024.
13. Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61: 365-369.
14. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL (2013) Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology 82: 60-65.
15. Harnden P, Naylor B, Shelly MD, Clements H, Coles B, Mason M (2008) The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer 112: 971-981.
16. Harrell FE (2001) Regression Modeling Strategies: with Applications to Linear Models. Logistic Regression, and Survival Analysis. Springer: New York, NY, USA.
17. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367: 595-605.
18. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H (2010) Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 11: 752-732.
19. Iremashvilli V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS (2012) Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 62: 462-468.
20. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10: 8472-8478.
21. Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR (2014) Racial Variation in Prostate Cancer Upgrading and Upstaging Among Men with Low-risk Clinical Characteristics. Eur Urol; e-pub ahead of print 5 April 2014; doi:10.1016/j.eururo.2014.03.026.
22. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771.
23. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat S, Slawin KM, Ohori M (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170: 1792-1797.
24. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2013) Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol 189: 867-870.
25. Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K. ProtecT Study Group (2010) Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. BJC 102: 1335-1340.
26. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW (1995) Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45: 831-838.
27. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58: 843-848.
28. Pepe MS (2004) The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press: New York, NY, USA.
29. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, Davis M, Catto JW, Avery K, Neal DE, Hamdy FC (2012) Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 344: d7894.
30. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. ERSPC Investigators (2009) Screening and prostate cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
31. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A. ERSPC Investigators (2012) Prostate-cancer mortality at 11 Years of follow-up. N Engl J Med 366: 981-990.
32. Shaw GL, Thomas BC, Dawson SN, Srivastava G, Vowler SL, Gnanapragasam VJ, Shah NC, Warren AY, Neal DE (2014) Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. BJC 110: 2405-2411.
33. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K (2006) Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238: 597-603.
34. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR (2013) Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 114: E18-E24.
35. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T. Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367: 203-213.
36. Zhou M, Tokumaru Y, Sidransky D, Epstein JI (2004) Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol 171: 2195-2198.